Melanoma Patients Matter – Report by Pharma

by Simon Rodwell | 8 May 2019 16:17

Melanoma Focus is pleased to share a new report, Melanoma Patients Matter, that has been published by the pharmaceutical company Bristol-Myers Squibb.

The NHS is committed to patients being at the heart of everything it does, and specifically ensuring patients are at the centre of any and all decisions made about their health. A diagnosis of melanoma often significantly changes a person’s life, so it is important that patients are informed, supported and empowered to make decisions that are right for them and give them the best opportunity to lead the life they want. Actively involving patients in their own care, treatment and support can lead to improved outcomes and experiences. 1

In order to understand how patients with melanoma are being involved in these decisions about their care and treatment, Melanoma Focus was invited by Bristol-Myers Squibb to share our experience and expertise in shaping the project and the resulting report, alongside the British Association of Skin Cancer Specialist Nurses (BASCSN), Melanoma Action and Support Scotland (MASScot) and Melanoma UK.

The views of patients across the UK with Stage 3 or Stage 4 melanoma were sought. The report found:

With the aim of ensuring all patients have the opportunity to be involved in their treatment and care, the report sets out a series of recommendations focused on improving the experiences of patients with melanoma, including:

This report, published by Bristol-Myers Squibb, is based on the results of a patient survey carried out in September 2018. We would like to thank all our supporters who responded to this survey for kindly sharing their insights and experiences of living with melanoma, and helping to identify key areas for improvement in care and support for patients with melanoma.

Follow this link to access a PDF copy of the report.

1 NHS England, Involving people in their own care. Available at: participation/. Last accessed: January 2019

Source URL: